Epclusa (Gilead Sciences, Inc.)
Welcome to the PulseAid listing for the Epclusa drug offered from Gilead Sciences, Inc.. This Hepatitis C Virus NS5A Inhibitor [EPC],Breast Cancer Resistance Protein Inhibitors [MoA],P-Glycoprotein Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA],Organic Anion Transporting Polypeptide 2B1 Inhibitors [MoA],Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC],RNA Replicase Inhibitors [MoA],Nucleoside Analog [Chemical/Ingredient] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Gilead Sciences, Inc. |
| NON-PROPRIETARY NAME: | Velpatasvir and Sofosbuvir |
| SUBSTANCE NAME: | VELPATASVIR; SOFOSBUVIR |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Hepatitis C Virus NS5A Inhibitor [EPC],Breast Cancer Resistance Protein Inhibitors [MoA],P-Glycoprotein Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA],Organic Anion Transporting Polypeptide 2B1 Inhibitors [MoA],Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC],RNA Replicase Inhibitors [MoA],Nucleoside Analog [Chemical/Ingredient] |
| ROUTE: | ORAL |
| DOSAGE FORM: | TABLET, FILM COATED |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2016-06-28 |
| END MARKETING DATE: | 0000-00-00 |
Epclusa HUMAN PRESCRIPTION DRUG Details:
| Item Description | Epclusa from Gilead Sciences, Inc. |
| LABELER NAME: | Gilead Sciences, Inc. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 100; 400(mg/1; mg/1) |
| START MARKETING DATE: | 2016-06-28 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 61958-2201_6ec61548-7bff-4619-99a0-d7fdc1c4cf59 |
| PRODUCT NDC: | 61958-2201 |
| APPLICATION NUMBER: | NDA208341 |
Other VELPATASVIR; SOFOSBUVIR Pharmaceutical Manufacturers / Labelers:
